ment Number: K11054C :: IV, Gavage :s/Strain: Mouse/B6C3F1	Toxicokinetics Data Summary Compound: Sulfolane/ Analyte: Sulfolane CAS Number: 126-33-0			Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Tl			
		Male					
Treatment Group (mg/kg)							
	10 IV Plasma ^b	10 Gavage Plasma ^a	30 Gavage Plasma ^a	100 Gavage Plasma ^a			
Cmax pred (ng/mL)	16800 ± 293	5840 ± 212	227000 ± 1090	97300 ± 6000			
Tmax_pred (hour)		0.227 ± 0.0160	0.290 ± 0.0276	0.369 ± 0.0553			
k01 (hour ⁻¹)		7.46 ± 1.23	6.68 ± 1.32	7.67 ± 1.76			
k01 Half-life (hour)		0.0929 ± 0.0153	0.104 ± 0.0206	0.0903 ± 0.0207			
k10 (hour ⁻¹)	2.33 ± 0.0474	2.32 ± 0.221	1.48 ± 0.177	0.553 ± 0.0546			
k10 Half-life (hour)	0.298 ± 0.00605	0.299 ± 0.0284	0.467 ± 0.0557	1.25 ± 0.124			
Cl (mL/h/kg)	1400 ± 20.3						
Cl1_F (mL/h/kg)		2350 ± 99.5	1270 ± 80.2	464 ± 38.7			
V1 (mL/kg)	602 ± 10.5						
V1_F (mL/kg)		1010 ± 93.8	859 ± 90.0	838 ± 72.8			
AUCinf_pred (h*ng/mL)	7200 ± 106	4270 ± 181	23600 ± 1480	216000 ± 18000			
F		59.2	109	299			

eriment Number: K11054C	Toxicokinetics Data Summary			Request Date: 7/11/2023			
ute: IV, Gavage Compound: Sulfolane/Analyte: Sulfolane				Request Time: 10:03:16			
cies/Strain: Mouse/B6C3F1	CAS Number: 126-33-0			Lab: TI			
		Female					
Treatment Group (mg/kg)							
	10 IV Plasma ^b	10 Gavage Plasma ^a	30 Gavage Plasma ^c	100 Gavage Plasma ^a			
Cmax pred (ng/mL)	15300 ± 492	6050 ± 173	24300 ± 1840	115000 ± 7300			
Tmax_pred (hour)		0.235 ± 0.0140	0.412 ± 0.0536	0.548 ± 0.0691			
k01 (hour ⁻¹)		8.31 ± 0.972	4.00 ± 1.33	4.02 ± 0.878			
k01 Half-life (hour)		0.0835 ± 0.00976	0.173 ± 0.0574	0.172 ± 0.0376			
k10 (hour ⁻¹)	1.89 ± 0.0721	1.80 ± 0.105	1.33 ± 0.298	0.626 ± 0.0625			
k10 Half-life (hour)	0.367 ± 0.0140	0.385 ± 0.0223	0.521 ± 0.116	1.11 ± 0.111			
Cl (mL/h/kg)	1300 ± 37.9						
Cl1_F (mL/h/kg)		1950 ± 65.4	950 ± 93.9	387 ± 33.0			
V1 (mL/kg)	687 ± 22.1						
V1_F (mL/kg)		1080 ± 61.6	713 ± 155	619 ± 66.1			
AUCinf_pred (h*ng/mL)	8090 ± 236	5130 ± 172	31600 ± 3120	258000 ± 22000			
F		63.4	139	319			

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: TI

LEGEND

MODELING SOFTWARE Phoenix WinNonlin (Version 6.3)

MODELING METHOD & BEST FIT MODEL

^a Phoenix WinNonlin (Version 6.3), For both rat and mouse, Model 1 (one-compartment with bolus intravenous dose and first order output) was used for intravenous data sets with individual time point data. Model 1 provided a good fit to the data.

^b Phoenix WinNonlin (Version 6.3), The best fit for both rat and mouse gavge data at all doses was Model 3 (one-compartment with first-order input and output, no lag time) with 1/y weighting. Mean time point data was used for gavage models.

EXCEPTIONS

^c 13-F-016 (female mouse, 30 mg/kg gavage group 45 min) was excluded from the analysis because it affected the fitted parameters to the extent it caused poor correlation between observed and predicted data.

ANALYTE

Sulfolane

TK PARAMETERS

- Cmax_pred = Observed or Predicted Maximum plasma (or tissue) concentration
- Tmax_pred = Time at which Cmax predicted or observed occurs
- k01 = Absorption rate constant, ka
- k01 Half-life = Half-life of the absorption process to the central compartment
- k10 = Elimination rate constant from the central compartment also ke or kelim
- k10 Half-life = Half-life for the elimination process from the central compartment
- CI = Clearance, includes total clearance
- Cl1_F = Apparent clearance of the central compartment, also Cl_F for gavage groups in non-compartmental model
- V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA, Vapp apparent volume of distribution for intravenous studies
- V1_F = Apparent volume of distribution for the central compartment includes Vd_F, V_F for oral groups, and Vc_F
- AUCinf = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity
- F = Bioavailability, absolute bioavailability

TK PARAMETERS PROTOCOL

ANALYSIS METHOD

Samples in which sulfolane was not detectable or where the concentration was less than the limit of detection (LOD) were not included in the analysis. If measured concentrations were between the LOD and the lower limit of quantitation (LLOQ), the value measured was used. For the determination of sulfolane in plasma, the LLOQ was 20.0 ng/mL, and the LOD was 0.516 ng/mL for both rat and mouse. The outliers 7-M-005 (male rat iv, 5 min), 8-F-008 (female rat iv, 15 min), and 13-F-016 (female mouse, 30 mg/kg gavage group 45 min) were excluded. Nominal doses (mg/kg) for each group were used in toxicokinetic modeling. Initial concentration versus time data were modeled using noncompartmental analysis methods using the mean concentration data at each time point but results were not reported. Various compartmental models were tested. One-compartmental models 3 (gavage) and 1 (ntravenous) were the best fit. For compartmental models AUC is calculated as Dose/V*K10 and is similar to AUCO-infinity. F = ((AUC/Dose(oral))/(AUC/Dose(iv)))*100.

Toxicokinetics Data Summary Compound: Sulfolane/ Analyte: Sulfolane CAS Number: 126-33-0 Request Date: 7/11/2023 Request Time: 10:03:16 Lab: TI

TK PARAMETERS PROTOCOL

TK_INTRAVENOUS PLASMA

10 mg/kg Male and Female

Thirty animals per group were given a single oral gavage administration of sulfolane in deionized water or a single intravenous dose in saline. Blood samples were taken at Predose, 5, 10, 15, 30, 45, 90, 180, 360, 540 minutes (9 post dose time points for 30 and 100 gavage dose both sexes), at Predose, 5 10, 15, 30, 45, 90, 120, 180, 240 minutes (9 post dose time points for 10 mg/kg gavage dose for both sexes) and at Predose, 5, 10, 15, 30, 45, 90, 120, 180, 240 minutes (9 post dose time points for intravenous doses for both sexes). Zero-hour collections were made pre-dose. n=3 per time point. Samples were analyzed by GC/MS using a validated method and sulfolane-d8 as an internal standard.

TK_GAVAGE PLASMA

10 mg/kg, 30 mg/kg, 100 mg/kg Male and Female

Thirty animals per group were given a single oral gavage administration of sulfolane in deionized water or a single intravenous dose in saline. Blood samples were taken at Predose, 5, 10, 15, 30, 45, 90, 180, 360, 540 minutes (9 post dose time points for 30 and 100 gavage dose both sexes), at Predose, 5 10, 15, 30, 45, 90, 120, 180, 240 minutes (9 post dose time points for 10 mg/kg gavage dose for both sexes) and at Predose, 5, 10, 15, 30, 45, 90, 120, 180, 240 minutes (9 post dose time points for both sexes). Zero-hour collections were made pre-dose. n=3 per time point. Samples were analyzed by GC/MS using a validated method and sulfolane-d8 as an internal standard.